Real world study of prostate cancer treatments
Part of Cancer, Kidney & urinary clinical trials.
This study looks at real-world data from men with metastatic castration-resistant prostate cancer (mCRPC) to understand what treatments they receive and how they do. It may help doctors learn more about which treatments work best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man diagnosed with metastatic castration-resistant prostate cancer (meaning the cancer has spread and no longer responds to hormone therapy) between January 2021 and December 2025.
- You are 18 years or older at the time of diagnosis.
- You are male.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) who have already used certain treatments, including a newer drug called lutetium-177 PSMA-617. It aims to understand how these treatments work and what happens to patients over time.
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This Phase 1 study tests a new drug that aims to attach to PSMA on prostate cancer cells and activate T-cells (an immune cell type) to attack the cancer. It is for men with advanced prostate cancer that no longer responds to hormone therapy, especially after several prior treatments.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests a new type of immune cell therapy (called AB-3028) designed to recognize and attack prostate cancer cells that have the PSMA protein on their surface. It's for people whose prostate cancer has spread and is no longer controlled by hormone therapy.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.